1997
DOI: 10.1007/bf02738965
|View full text |Cite
|
Sign up to set email alerts
|

Nasal calcitonin

Abstract: Nasal calcitonin is a newly approved treatment for established osteoporosis that increases lumbar spine bone mass, is safe, and well tolerated. Fracture efficacy data is not yet available, although preliminary results are promising. The dose for established osteoporosis is 200 IU. The dose for prevention of postmenopausal osteoporosis has not been established. Nasal calcitonin may be analgesic to bone and may be of benefit in glucocorticoid-induced vertebral osteoporosis. Nasal spray calcitonin may be of benef… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
4
0

Year Published

1998
1998
2015
2015

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(4 citation statements)
references
References 25 publications
0
4
0
Order By: Relevance
“…The major side effects are transient nausea and facial flushing. Nasal calcitonin causes less nausea, but 11% of patients develop rhinitis 76 . When administered by either route, calcitonin leads to a prompt fall in urine collagen cross‐link excretion, followed by a fall in serum alkaline phosphatase after several weeks.…”
Section: Assessment Of Disease Activity In Paget's Diseasementioning
confidence: 99%
See 1 more Smart Citation
“…The major side effects are transient nausea and facial flushing. Nasal calcitonin causes less nausea, but 11% of patients develop rhinitis 76 . When administered by either route, calcitonin leads to a prompt fall in urine collagen cross‐link excretion, followed by a fall in serum alkaline phosphatase after several weeks.…”
Section: Assessment Of Disease Activity In Paget's Diseasementioning
confidence: 99%
“…Gallium nitrate: Gallium nitrate, a potent antiresorptive drug, is currently an experimental therapy for Paget's disease of the bone 76–78 . In a multicenter trial, gallium nitrate was administered at doses of 0.05, 0.25, and 0.5 mg/kg/day by subcutaneous injection in two 14‐day cycles.…”
Section: Assessment Of Disease Activity In Paget's Diseasementioning
confidence: 99%
“…It is known that the nervous system varies in its susceptibility to toxicant-induced damage with age (e.g., [3][4][5][6][7][8][9][10][11][12]). Given the potential for olfactory mucosal metabolism of compounds, especially the multitude of drugs under development for intranasal administration (e.g., [13][14][15][16][17][18]), it is important to know the metabolic enzymes present in the olfactory mucosa, as well as how the expression and activity of these enzymes change with age. In addition, N-acetyltransferase activities in the olfactory mucosa are described; these enzymes are likely involved in the metabolism of multiple nasal carcinogens, encountered as either environmental contaminants or as metabolites of therapeutically administered drugs.…”
Section: Introductionmentioning
confidence: 99%
“…Clinical interventions for bone health in women with physical disabilities require tailoring to individual health needs. Calcitonin nasal spray is effective on a short‐term basis, particularly for women with vertebral compression fractures (Silverman, 1997). Each of the bisphosphonates has specific uses for women with physical disabilities.…”
mentioning
confidence: 99%